

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
11 April 2002 (11.04.2002)

PCT

(10) International Publication Number
WO 02/28373 A1

(51) International Patent Classification⁷: **A61K 9/20**,
31/415, 31/135, A61P 37/08

Aires (AR). **VIDAL, Marta, Cicconi de** [AR/AR];
Ituzaingo 4156, 1754 San Justo, Buenos Aires (AR).

(21) International Application Number: PCT/EP01/11229

(22) International Filing Date:
28 September 2001 (28.09.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
00121828.8 6 October 2000 (06.10.2000) EP

(71) Applicant (for all designated States except US):
BOEHRINGER INGELHEIM INTERNATIONAL
GMBH [DE/DE]; 55216 Ingelheim am Rhein (DE).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,
CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,
MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI,
SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU,
ZA, ZW.

(84) Designated States (*regional*): ARIPO patent (GI, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian
patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European
patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE,
IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF,
CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD,
TG).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **ABELAIRA, Sara**
[AR/AR]; Salazar 1483, 1686 Hurlingham, Buenos Aires
(AR). **BIANCHI, Daniel** [AR/AR]; Bulnes 2736 (P. 15,
Dpto. 05), 1425 Buenos Aires (AR). **GEL, Francisco**
[AR/AR]; Vicente Damonte 1520, (1824) Lanus Este,
Buenos Aires (AR). **DENKER, Victor** [AR/AR]; Men-
doza 2295, 1428 Buenos Aires (AR). **FERNANDEZ,**
Mabel [AR/AR]; Marconi 4848, 1605 Munro, Buenos

Published:

— with international search report
before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments

For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.

WO 02/28373 A1

(54) Title: NEW PHARMACEUTICAL COMPOSITIONS CONTAINING EPINASTINE AND PSEUDOEPHEDRINE

(57) Abstract: The present invention relates to novel oral pharmaceutical compositions comprising as pharmaceutically active com-
pounds a combination of an antihistaminic-effective amount of epinastine or a pharmaceutically acceptable salt thereof and of a
decongestant-effective amount of pseudoephedrine or a pharmaceutically acceptable salt thereof and further comprising suitable
pharmaceutically acceptable carriers or excipients. The invention further relates to methods for the preparation these compositions
and methods of using them in the treatment of allergic diseases and/or disorders.

New pharmaceutical compositions containing epinastine and pseudoephedrineBackground of the invention

The present invention relates to novel oral pharmaceutical compositions comprising
5 as pharmaceutically active compounds a combination of an antihistaminic-effective
amount of epinastine or a pharmaceutically acceptable salt thereof and of a
decongestant-effective amount of pseudoephedrine or a pharmaceutically
acceptable salt thereof and further comprising suitable pharmaceutically acceptable
carriers or excipients. The invention further relates to methods for the preparation
10 these compositions and methods of using them in the treatment of allergic diseases
and/or disorders.

Description of the invention

The present invention provides for novel oral pharmaceutical compositions
comprising as pharmaceutically active compounds a combination of an
15 antihistaminic-effective amount of epinastine or a pharmaceutically acceptable salt
thereof and of a decongestant-effective amount of pseudoephedrine or a
pharmaceutically acceptable salt thereof and further comprising pharmaceutically
acceptable carriers or excipients under the proviso that the composition does not
contain a leukotriene antagonist.

20

As an additional active compound the compositions according to the invention may
optionally contain one or several compounds selected from the group consisting of
mucolytic and analgesic-antipyretic compounds and vitamins. Preferred mucolytic
ingredients are selected from bromhexine and ambroxol. Preferred analgesic-
25 antipyretic compounds are selected from paracetamol and ibuprofen. Preferred
vitamins are selected from vitamin B2, B6 and C.

The pharmaceutical compositions according to the invention are useful for the
treatment of allergic rhinitis, allergic congestion of the Eustachian tubes and / or
30 other diseases from allergic origin deserving the administration of antihistamine and
decongestant drugs. Furthermore the compositions according to the invention are
useful in the treatment of for instance common cold and in the symptomatic relief
associated with cough, cold and flu symptoms. The use of the pharmaceutical
compositions according to the invention for the treatment of allergic rhinitis, allergic

congestion of the Eustachian tubes and / or other diseases from allergic origin deserving the administration of antihistamine and decongestant drugs is preferred.

In a preferred embodiment the pharmaceutical composition according to the
5 invention contains as the active ingredients only an antihistaminic-effective amount of epinastine or a pharmaceutically acceptable salt thereof and a decongestant-effective amount of pseudoephedrine or a pharmaceutically acceptable salt thereof

In a preferred embodiment the present invention relates to an oral pharmaceutical
10 composition, preferably a bilayer tablet, providing for a sustained release of the decongestant effective amount of pseudoephedrine and an immediate release of an antihistaminic effective amount of epinastine.

Particularly preferred according to the invention is a bilayer tablet wherein a first
15 layer A, providing for the sustained release of pseudoephedrine, comprises a decongestant effective amount of pseudoephedrine or a pharmaceutically acceptable salt thereof and wherein a second layer B, providing for the immediate release of epinastine, comprises an antihistaminic effective amount of epinastine or a pharmaceutically acceptable salt thereof. The bilayer tablet according to the
20 invention may additionally contain a tablet coating C consisting of pharmaceutically acceptable excipients which mask the bitter taste of one of the active compounds.

In a preferred embodiment of the invention layer A of the bilayer tablet according to the invention comprises a decongestant effective amount of pseudoephedrine or a
25 pharmaceutically acceptable salt thereof in a matrix of a swellable hydrophilic polymer which provides a sustained release profile in a period of 3 to 24, preferably 6 to 18, most preferably about 12 hours.

According to the invention the term pharmaceutically acceptable salts stands for acid
30 addition salts of the active compounds pseudoephedrine and epinastine. These acid addition salts can be formed with anorganic acids like hydrochloric acid, hydrobromic acid or sulfuric acid or with organic acids as for instance oxalic acid, fumaric acid or methansulfonic acid. Epinastine is preferably used as its hydrochloric acid addition

salt. Pseudoephedrine is preferably used as the hydrochloride or the sulfate. Within the present invention pseudoephedrine sulfate is most preferred.

The release of pseudoephedrine takes place over 3 to 24, preferably 6 to 18, most preferably about 12 hours. This bilayer tablet is designed to be preferably administered twice daily.

The concentration range of pseudoephedrine salt in the compositions according to the invention is between 5 and 240 mg/tablet, preferably 10 to 200 mg/tablet, more preferably 60 to 180 mg/tablet, preferably 80 to 140 mg/tablet, most preferably 120 mg/tablet. The concentration range of epinastine salt in the compositions according to the invention is between 2 and 20 mg/tablet, preferably 5 to 10 mg/tablet, more preferably 10 mg/tablet.

Each layer of the tablet is in contact with each other in a portion of their surface, but provides independent release profiles for both active substances mentioned before. The sustained release layer A consists of pseudoephedrine or a pharmaceutically acceptable salt thereof and a swellable hydrophilic polymer.

Typical swellable hydrophilic polymers include cellulosic ethers such as methylcellulose, hydroxypropylcellulose, hydroxypropylmethylcellulose, hydroxymethylcellulose, hydroxyethylcellulose, carboxymethylcellulose and carboxyethylcellulose or mixtures thereof. The use of hydroxypropylmethylcellulose (HPMC) is preferred. Particularly useful are the HPMC polymers HPMC USP2910 and USP2208 like for instance Methocel E5, E4M, E15M, K15M, and K100M supplied by the Dow Chemical Company. In the aforementioned abbreviations the designation "E" refers to USP2910 whereas "K" refers to USP2208. The number designation refers to the viscosity in a 2% aqueous solution (e.g. 5 designates a viscosity of 5 cps; 15M designates a viscosity of 15000 cps).

The excipients that could be optionally used in the sustained release layer A, are insoluble polymers, soluble or insoluble fillers, antiadherents, coloring agents, lubricants and additional binders. Typical fillers are for example lactose, microcrystalline cellulose, dibasic calcium phosphate and cornstarch. Examples of antiadherents, which are used to prevent tablets from sticking to the tablet press, are

colloidal silicon dioxide and talc. Magnesium stearate, talc and stearic acid are typical lubricants. Typical binders are povidone, and cornstarch.

The immediate release matrix layer B comprises epinastine within different combinations of excipients. The excipients that could be optionally used in the immediate release layer B are insoluble polymers, soluble or insoluble fillers, antiadherents, lubricants, coloring agents, disintegrants and additional binders. Typical fillers are for example lactose, microcrystalline cellulose, dibasic calcium phosphate and cornstarch. Examples of antiadherents, which are used to prevent tablets from sticking to the tablet press, are colloidal silicon dioxide and talc. Typical disintegrants are croscopovidone, sodium starch glycolate and crosscarmellose sodium. Typical coloring agents are selected from FD&C red 40 HT Aluminum lake, 2-hydroxy-1,1'-azonaphthalene-3,6,4'-trisulfonic acid trisodium salt, erythrosine, iron oxides, 1-(4-sulpho-1-naphthylazo)-2-naphthol-6,8-disulphonic acid trisodium salt, 2',4',5',7'-tetrabromo-4,5,6,7-tetrachloro-fluorescein disodium salt, 2,4,5,7-Tetraiodo-3,6-dihydroxyxanthene-9-spiro-1'-(4',5',6',7'-tetrachloro-3'H-isobenzofuran-3'one dipotassium salt, trisodium 3-carboxy-5-hydroxy-1-p-sulphophenyl-4-p-sulphophenylazopyrazole, 6-hydroxy-5-((4-sulphonphenyl)azo-2-naphthalenésulphonic acid disodium salt and optionally aluminium lakes thereof. Magnesium stearate, talc and stearic acid are typical lubricants. Typical binders are povidone, and cornstarch.

Water and ethanol are examples of volatile components which can be used in the manufacture process of both layers to granulate powders. These volatile components are removed during processing and therefore do not appear in the finished product.

The tablet coating is optional since the presence of it does not modifies significantly the release rates of the active substances present in the core layers. The presence of the coating is preferred because it masks the bitter taste of one of the active substances and enhances the properties of dosage form. Because of that a lot different coatings with different polymers, and plasticizers and other excipients could be used with the condition of not modifying significantly the release profile of the active substances present in the core tablet. A typical coating comprises a polymer such as hydroxypropylmethylcellulose and a plasticizer such as polyethylene glycol.

5

Optional excipients could be added to the coating like antifoaming agents and opacifying. Example of an antifoaming agent is silicone. Examples of opacifying agents are Titanium dioxide, talc and aluminum lake dyes.

- 5 The invention will be further described by the following examples. These examples disclose certain preferred embodiments of the invention. The methods of manufacturing the compositions according to the invention like for instance granulation, tablet compression, tablet coating etc. are well known to the person skilled in the art. Those skilled in the art will appreciate that various changes,
- 10 modifications and substitutions can be made therein without departing from the spirit of the invention. Accordingly, it is intended that the invention be not limited to the following explicitly disclosed examples.

Example N°1 - Composition

15 **Core**

A. First layer

<u>Layer pseudoephedrine</u>	mg/tablet
Pseudoephedrine sulfate	120.00
Methocel K 15 M PRCR *	198.00
Lactose Monohydrate	105.10
Microcrystalline cellulose	106.00
Colloidal silicon dioxide	1.65
Magnesium Stearate	2.75
Povidone	16.50
Total first layer	550.00

B. Second layer

<u>Layer Eplnastine</u>	mg / tablet
Epinastine HCl	10.00
FD&C red 40 HT Aluminum lake (allura red AC)	0.38
Microcrystalline cellulose	70.00
Lactose Monohydrate	154.62
Povidone	12.50

6

Magnesium Stearate	2.50
Total second layer	250.00

Total core	800.00
-------------------	---------------

C. Coating

Film Coating	mg/ tablet
Methocel E5	15.00
Polyethylene Glycol 6000	1.97
Silicone antifoam S184	0.03
Total film coating	17.00

Total Film coated tablet	817.00
---------------------------------	---------------

5 * PR means Premium grade and CR means Controlled Released grade.

Method of ManufactureA. First layer:

- A1. Dissolve povidone in a hydroalcoholic mixture;
- A2. Blend pseudoephedrine sulfate, a portion of the microcrystalline cellulose,
10 lactose and Methocel K15M for 5-30 minutes in a suitable mixer.
- A3. Use alcoholic or hydroalcoholic solution prepared previously in step A1. to granulate the powder mix.
- A4. Dry and mill the pseudoephedrine sulfate granulation from step A3, using suitable size screen.
- 15 A5. Blend the screened pseudoephedrine sulfate granulation with a portion of the microcrystalline cellulose and colloidal silicon dioxide for 3-15 minutes.
- A6. Add magnesium stearate and blend for 3-15 minutes.

B. Second layer:

- 20 B1. Pass through a suitable screen Epinastine HCL, Allura red AC (FD & C red 40 HT) aluminum lake and microcrystalline cellulose. Blend for 5-30 minutes in a suitable mixer.
- B2. Add lactose and povidone. Blend for 60 minutes 15-120 minutes in a suitable mixer.
- 25 B3. Add magnesium stearate. Blend for 3-20 minutes in a suitable mixer.

C. Compression:

Compress A and B into a suitable bilayer tableting machine in suitable size tablets.

5 D. Coating

D1. Dissolve Methocel E5 and Polyethylene Glycol in suitable amount of water.

D2. Dissolve silicone antifoam in suitable amount of isopropilic alcohol.

D3. Add 2. to 1. and mix.

D4. Coat tablets with the Methocel E5 /Polyethylene glycol solution from step D3. in
10 a suitable coater.

Example N° 2 - CompositionCore**A. First layer**

<u>Layer pseudoephedrine</u>	Mg/tablet
Pseudoephedrine sulfate	120.00
Methocel K 15 M PRCR *	198.00
Lactose Monohydrate	126.50
Microcrystalline cellulose	100.00
Colloidal silicon dioxide	2.75
Magnesium Stearate	2.75
Total first layer	550.00

15

B. Second layer

<u>Layer Epinastine</u>	Mg / tablet
Epinastine HCl	10.00
Lactose Monohydrate	168.40
Microcrystalline cellulose	70.00
Puncheon 4R red aluminum lake	0.38
Magnesium Stearate	1.25
Total second layer	250.00

Total core	800.00
-------------------	---------------

C. Coating

Film Coating	mg/ tablet
Methocel E5	4.42
Polyethylene Glycol 6000	2.72
Talc	8.76
Titanium dioxide	1.10
Total film coating	17.00

Total Film coated tablet	817.00
---------------------------------	---------------

5

* PR means Premium grade and CR means Controlled Released grade.

Method of Manufacture**A. First layer:**

- 10 A1. Blend pseudoephedrine sulfate, microcrystalline cellulose, lactose, colloidal
silicon dioxide and HPMC K15M for 5-30 minutes in a suitable mixer.
- A2. Add magnesium stearate and blend for 3-15 minutes.

B. Second layer:

- 15 B1. Pass through a suitable screen Epinastine HCl, and microcrystalline cellulose.
Blend for 5-30 minutes in a suitable mixer.
- B2. Add lactose. Blend for 60 minutes 15-120 minutes in a suitable mixer.
- B3. Add magnesium stearate. Blend for 3-20 minutes in a suitable mixer.

C. Compression:

- 20 Compress A and B into a suitable bilayer tableting machine in suitable size tablets.

D. Coating

- D1. Dissolve Methocel E5 and Polyethylene Glycol in suitable amount of water.
- D2. Add Titanium Dioxide and Talc in suitable amount of water and mix
- 25 D3. Add 2. to 1. And mix.

D4. Coat tablets with the Methocel E5 /Polyethylene glycol solution from step D3. In a suitable coater.

Example N° 3

5 Core

A. First layer

<u>Layer pseudoephedrine</u>	<u>Mg/tablet</u>
Pseudoephedrine sulfate	120.00
Methocel K4M PRCR	247.50
Lactose Monohydrate	166.00
Talc	11.00
Magnesium Stearate	5.50
Total first layer	550.00

* PR means Premium grade and CR means Controlled Released grade.

Second layer and coating are identical to example 2; the manufacture method was
10 conducted analogously to the method outlined in example 2;

Example N° 4

Core

A. First layer

<u>Layer pseudoephedrine</u>	<u>Mg/tablet</u>
Pseudoephedrine sulfate	120.00
Methocel K15 M PRCR	198.00
Lactose Monohydrate	99.50
Microcrystalline cellulose	99.50
Colloidal silicon dioxide	2.75
Povidone	27.50
Magnesium stearate	2.75
Total	550.00

* PR means Premium grade and CR means Controlled Released grade.

15

Second layer and coating are identical to example 1; the manufacture method was conducted analogously to the method outlined in example 1;

Exempl N° 5Core**A. First layer**

<u>Layer pseudoephedrine</u>	Mg/tablet
Pseudoephedrine sulfate	120.00
Methocel K15M CR	330.00
Lactose	83.50
Talc	11.00
Magnesium Stearate	5.50
Total	550.00

5

* CR means Controlled Released grade.

Second layer and coating are identical to example 1; the manufacture method was conducted analogously to the method outlined in example 1;

10 Example N° 6Core**A. First layer**

<u>Layer pseudoephedrine</u>	Mg/tablet
Pseudoephedrine sulfate	120.00
Methocel K15M CR	275.00
Microcrystalline Cellulose	138.50
Talc	11.00
Magnesium Stearate	5.50
Ethanol	sq.
Total	550.00

* CR means Controlled Released grade.

15 Second layer and coating are identical to example 1; the manufacture method was conducted analogously to the method outlined in example 1;

Example N° 7Core**A. First layer**

<u>Layer pseudoephedrine</u>	Mg/tablet
Pseudoephedrine sulfate	120.00
Methocel K15M CR	215.00
Dibasic Calcium phosphate	108.50
Ethylcellulose	40.00
Talc	11.00
Magnesium Stearate	5.50
Ethanol	s.q.
Total	500.00

* CR means Controlled Released grade.

5

Second layer and coating are identical to example 1; the manufacture method was conducted analogously to the method outlined in example 1;

Example N° 810 Core**A. First layer**

<u>Layer pseudoephedrine</u>	Mg/tablet
Pseudoephedrine sulfate	120.00
Methocel K15M CR	137.50
Methocel K100M CR	137.50
Lactose	138.50
Talc	11.00
Magnesium Stearate	5.50
Ethanol	s.q.
Total	550.00

* CR means Controlled Released grade.

15 Second layer and coating are identical to example 1; the manufacture method was conducted analogously to the method outlined in example 1;

Example N° 9Core**A. First layer**

<u>Layer pseudoephedrine</u>	Mg/tablet
Pseudoephedrine sulfate	120.00
Methocel K100M CR	275.00
Lactose	138.50
Talc	11.00
Magnesium Stearate	5.50
Ethanol	s.q.
Total	550.00

* CR means Controlled Released grade.

5

Second layer and coating are identical to example 1; the manufacture method was conducted analogously to the method outlined in example 1;

Example N° 1010 Core**A. First layer**

<u>Layer pseudoephedrine</u>	Mg/tablet
Pseudoephedrine sulfate	120.00
Methocel K15M CR	206.20
Methocel K100M CR	68.80
Lactose	138.50
Talc	11.00
Magnesium Stearate	5.50
Ethanol	s.q.
Total	550.00

* CR means Controlled Released grade.

15 Second layer and coating are identical to example 1; the manufacture method was conducted analogously to the method outlined in example 1;

Example N° 11Core**A. First layer**

<u>Layer pseudoephedrine</u>	Mg/tablet
Pseudoephedrine sulfate	120.00
Methocel K15M CR	235.00
Dibasic Calcium phosphate	108.50
Ethylcellulose	20.00
Talc	11.00
Magnesium Stearate	5.50
Ethanol	s.q.
Total	500.00

* CR means Controlled Released grade.

5

Second layer and coating are identical to example 1; the manufacture method was conducted analogously to the method outlined in example 1;

Example N° 1210 Core**A. First layer**

<u>Layer pseudoephedrine</u>	Mg/tablet
Pseudoephedrine sulfate	120.00
Methocel K15M CR	255.00
Lactose	40.00
Microcrystalline Cellulose	68.50
Talc	11.00
Magnesium Stearate	5.50
Ethanol	s.q.
Total	500.00

* CR means Controlled Released grade.

15 Second layer and coating are identical to example 1; the manufacture method was conducted analogously to the method outlined in example 1;

Example N° 13Core**A. First layer**

<u>Layer pseudoephedrine</u>	<u>Mg/tablet</u>
Pseudoephedrine sulfate	120.00
Methocel K15M CR	255.00
Dibasic calcium phosphate	108.50
Talc	11.00
Magnesium Stearate	5.50
Ethanol	s.q.
Total	500.00

* CR means Controlled Released grade.

5

Second layer and coating are identical to example 1; the manufacture method was conducted analogously to the method outlined in example 1;

Claims

- 1) Oral pharmaceutical compositions comprising as pharmaceutically active compounds a combination of an antihistaminic-effective amount of epinastine
5 or a pharmaceutically acceptable salt thereof and of a decongestant-effective amount of pseudoephedrine or a pharmaceutically acceptable salt thereof and further comprising pharmaceutically acceptable carriers or excipients under the proviso that the composition does not contain a leukotriene antagonist.
- 10 2) Oral pharmaceutical composition according to claim 1, characterized in that it contains as the active ingredients only an antihistaminic-effective amount of epinastine or a pharmaceutically acceptable salt thereof and a decongestant-effective amount of pseudoephedrine or a pharmaceutically acceptable salt thereof.
- 15 3) Oral pharmaceutical composition according to claim 1 or 2, providing for a sustained release of the decongestant effective amount of pseudoephedrine and an immediate release of an antihistaminic effective amount of epinastine.
- 20 4) Oral pharmaceutical composition according to claims 1, 2 or 3, characterized in that it represents a bilayer tablet.
- 5) Bilayer tablet according to claim 4, wherein a first layer A, providing for the sustained release of pseudoephedrine, comprises a decongestant effective
25 amount of pseudoephedrine or a pharmaceutically acceptable salt thereof and wherein a second layer B, providing for the immediate release of epinastine, comprises an antihistaminic effective amount of epinastine or a pharmaceutically acceptable salt thereof.
- 30 6) Bilayer tablet according to claim 5, characterized in that it additionally contains a tablet coating C consisting of pharmaceutically acceptable excipients.

16

- 7) Bilayer tablet according to claim 4, 5 or 6, characterized in that layer A comprises a decongestant effective amount of pseudoephedrine or a pharmaceutically acceptable salt thereof in a matrix of a swellable hydrophilic polymer.

5

- 8) Bilayer tablet according to claim 4, 5, 6 or 7, characterized in that the concentration range of pseudoephedrine salt is 5 and 240 mg/tablet and the concentration range of epinastine salt in the compositions according to the invention is between 2 and 20 mg/tablet.

10

- 9) Bilayer tablet according to one of claims 4 to 8, characterized in that layer A comprises 120 mg pseudoephedrine sulfate and layer B comprises 10 mg epinastine-HCl.

- 15 10) Use of a pharmaceutical composition according to one of claims 1 to 9 for the treatment of allergic rhinitis, allergic congestion of the Eustachian tubes and / or other diseases from allergic origin deserving the administration of antihistamine and decongestant drugs, in the treatment of for instance common cold and in the symptomatic relief associated with cough, cold and flu symptoms.

20

- 11) Use of a pharmaceutical composition according to claim 10 for the treatment of allergic rhinitis, allergic congestion of the Eustachian tubes and / or other diseases from allergic origin deserving the administration of antihistamine and decongestant drugs, preferably of allergic rhinitis.

25

INTERNATIONAL SEARCH REPORT

Intern al Application No

PCT/EP 01/11229

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 A61K9/20 A61K31/415 A61K31/135 A61P37/08

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

WPI Data, PAJ, EPO-Internal, CHEM-ABS Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 99 32125 A (SCHERING) 1 July 1999 (1999-07-01) claims 1,7,8 page 9, line 25 - line 33	1-11
A	EP 0 903 151 A (ASTA) 24 March 1999 (1999-03-24) the whole document	1-11
P,X	WO 01 51038 A (LABORATORIOS PHOENIX) 19 July 2001 (2001-07-19) claims 1,2,22 page 5, line 11 - line 13 examples 1,6	1-8,10, 11



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

* Special categories of cited documents:

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *I* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *G* document member of the same patent family

Date of the actual completion of the international search

6 February 2002

Date of mailing of the international search report

15/02/2002

Name and mailing address of the ISA

European Patent Office, P.B. 5618 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Ventura Amat, A

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No
PCT/EP 01/11229

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 9932125	A	01-07-1999	AU 1907199 A BR 9814417 A CN 1283115 T EP 1041990 A1 NO 20003288 A PL 341343 A1 SK 8972000 A3 WO 9932125 A1 ZA 9811731 A	12-07-1999 10-10-2000 07-02-2001 11-10-2000 22-08-2000 09-04-2001 12-02-2001 01-07-1999 21-06-1999
EP 903151	A	24-03-1999	EP 0903151 A1 AU 9540098 A BR 9812361 A DE 19882573 T0 WO 9915203 A1 JP 2001517639 T NO 20001459 A PL 339541 A1 ZA 9808638 A	24-03-1999 12-04-1999 19-09-2000 26-10-2000 01-04-1999 09-10-2001 21-03-2000 18-12-2000 23-03-1999
WO 0151038	A	19-07-2001	AU 2634901 A WO 0151038 A1	24-07-2001 19-07-2001